Semaglutide and tirzepatide constitute powerful tools for the medical treatment of clinical obesity, a chronic disease that results from altered organ function or physical functioning owing to excess adiposity.1 For the 90% of patients with type 2 diabetes who have overweight or obesity,2 these drugs offer simultaneous treatment of the two diseases. The diverse metabolic and physical manifestations and complications of obesity respond differentially to treatment, and algorithms to guide individualized treatment intensity are needed, similar to those developed for the treatment of other chronic diseases such as diabetes and hypertension.3 Given the varied individual efficacy and side effects of . . .
Craig M. Hales (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: